Top Story Today
Gilead's $7.8 Billion Bet on a Protein That Could Reshape the CAR-T Market
Gilead is paying $7.8 billion to acquire Arcellx and its D-Domain protein, a synthetic binding molecule one-third the size of traditional CAR-T components that eliminates the clumping and burnout problems plaguing current therapies. The deal's centerpiece, anito-cel, posted a 100% response rate in Phase 1 and 96% in the pivotal Phase 2 for multiple myeloma, with almost entirely mild side effects. It transforms the BCMA myeloma market from a J&J/BMS duopoly into a three-way fight, with an FDA decision set for December 2026.
Why it matters: With its existing Kite CAR-T franchise shrinking 7% year over year, Gilead isn't just buying a drug; it's buying a platform that could generate next-generation cell therapies across multiple cancer types, reshaping the competitive balance of a $7 billion market.
Read more →Deals and M&A
Biogen Drops $5.6 Billion on an Eye Drug Company Trading at $17
A 140% premium tells you how beaten down Apellis was. Biogen is paying $5.6 billion for Syfovre, the first-ever therapy for geographic atrophy, which holds 60% market share and pulled in $587 million in 2025. The deal catapults Biogen into ophthalmology and rare kidney disease, with contingent payments of up to $4 more per share tied to Syfovre hitting $2 billion in annual sales.
Read more →Sun Pharma Makes the Largest Overseas Acquisition in Indian Pharma History
Sun Pharma is buying Organon for $11.75 billion, nearly triple the size of the previous Indian pharma M&A record. At roughly 6x EBITDA, analysts call it disciplined pricing despite $8.6 billion in inherited debt. The combined company would crack the top 25 global pharma firms, with $12.4 billion in revenue and a top-3 position in women's health.
Read more →Merck Pays $6.7 Billion for a Stock That Cost $3 Thirteen Months Ago
Terns Pharmaceuticals went from $3 to a $53 buyout, a 1,900% gain fueled by one CML drug showing response rates two to three times higher than the competition. Merck needs the pipeline badly: Keytruda's core patent expires in December 2028, and the company faces roughly $18 billion in cumulative revenue losses over five years.
Read more →Clinical Breakthroughs
A Once-Daily Pill Nearly Doubled Survival in Pancreatic Cancer
Revolution Medicines' oral RAS inhibitor daraxonrasib delivered 13.2 months median overall survival versus 6.7 months on chemo in advanced pancreatic cancer, a disease where gains are usually measured in weeks. The stock surged 40%. The survival benefit was so large that the interim analysis was declared final, and Revolution plans to file for FDA approval.
Read more →Bayer's Blood Thinner Cut Stroke Risk 26% Without Extra Bleeding
After years of class-wide failures, asundexian became the first FXIa inhibitor to deliver clean Phase 3 results, reducing recurrent stroke by 26% while keeping major bleeding rates statistically identical to placebo. The FDA granted priority review. For stroke survivors undertreated because of bleeding fears, this could open a significant new option.
Read more →Lilly's Last-Resort Cancer Drug Just Aced a Frontline Test
Jaypirca, built as a salvage therapy, cut the risk of disease progression by roughly 80% in untreated CLL patients versus standard chemo. At two years, 93.4% of patients on the drug hadn't progressed. The data threatens a $10-12 billion BTK inhibitor market currently dominated by AbbVie, AstraZeneca, and BeiGene.
Read more →Pfizer's mRNA Flu Shot Beat the Standard Vaccine by 34.5%
In a head-to-head Phase 3 trial against Sanofi's Fluzone, Pfizer's mRNA flu vaccine reduced lab-confirmed influenza by 34.5%. It crushed influenza A strains but stumbled on B-strain immunogenicity, a weakness that's also plaguing the company's flu/COVID combo program. Moderna may still reach the market first.
Read more →Science and Discovery
Legend Biotech Built Cancer-Killing Cells Inside a Patient's Body
No factory. No cell collection. No lymphodepleting chemo. Legend's LB2501 delivered CAR-T instructions directly into patients' bloodstreams via a single IV infusion, and at the higher dose, all six patients responded with five achieving complete responses. Zero neurotoxicity. If this approach scales, it could dismantle the most complex supply chain in medicine.
Read more →Allogene's Off-the-Shelf CAR-T Cleared Cancer at Triple the Rate of Observation
In a pivotal trial, 58.3% of patients on Allogene's donor-derived CAR-T cleared molecular traces of cancer versus 16.7% on observation. Zero CRS, zero neurotoxicity, zero graft-versus-host disease. If scaled manufacturing drops costs from $373,000–$475,000 to under $20,000 per dose, cell therapy could finally become accessible beyond elite academic centers.
Read more →J&J's $5 Billion Anti-Tau Alzheimer's Drug Joins the Graveyard
Posdinemab failed its Phase 2b trial across every endpoint, becoming the sixth major tau antibody to flop in Alzheimer's. The mid-domain targeting strategy was supposed to be the smarter approach; it wasn't. J&J killed the program, but the broader question looms: tau clearly drives cognitive decline, so why can't anyone build a drug that stops it?
Read more →